{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:17:12Z","timestamp":1787167032131,"version":"build-2736575974"},"reference-count":16,"publisher":"Journal of Biological Methods","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HPR"],"abstract":"<jats:p>Objective\nAre individuals who use hallucinogens self-medicating their mental illness and are they more likely to abuse other illegal substances?\n&amp;nbsp;\nDesign, setting, participants\nData from the National Survey on Drug Use and Health (NSDUH), collected by the Substance Abuse and Mental Health Services Administration (SAMHSA) database was queried for correlations with hallucinogen use. Using age group as a control variable, different variables were run through a crosstab in order to find significant data pointing to the implications of hallucinogen use.\n&amp;nbsp;\nResults\nThe data from the crosstab analysis showed three key findings about hallucinogen use: Those with mental illness or substance abuse issues were substantially more likely to use hallucinogens, the hallucinogen use greatly increased with the pandemic along with further mental health issues, and those who used hallucinogens were more significantly likely to abuse other illegal substances, primarily in a younger population.\n&amp;nbsp;\nConclusion\nThe positive correlation between mental health issues and hallucinogen use emphasizes the need for better mental health services, especially after the COVID-19 pandemic.\nThe positive correlation between hallucinogen use and other drug use indicates the widespread drug abuse problem, especially within a younger population in which drugs pose a larger neurological threat.<\/jats:p>","DOI":"10.52965\/001c.127794","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T18:06:19Z","timestamp":1736186779000},"page":"1","source":"Crossref","is-referenced-by-count":3,"title":["The Psych Behind Psychedelics: Exploring Hallucinogen Use as a Marker for Untreated Mental Health Disorders"],"prefix":"10.14440","volume":"13","author":[{"given":"Liyana","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Konda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5574","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01015-9","article-title":"Suicidal thoughts and behaviors among untreated illicit substance users: a population-based study","volume":"21","author":"R. Shiraly","year":"2024","journal-title":"Harm Reduction Journal"},{"key":"ref2","article-title":"National Survey on Drug Use and health","journal-title":"SAMHSA.gov"},{"issue":"7","key":"ref3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/02698811231158245","article-title":"Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020","volume":"37","author":"E. I. Kopra","year":"2023","journal-title":"Journal of Psychopharmacology"},{"issue":"18","key":"ref4","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.3390\/nu14183868","article-title":"Lifestyle Changes, Emotional Eating, Gender, and Stress during COVID-19 Lockdown","volume":"14","author":"D. Hadar-Shoval","year":"2022","journal-title":"Nutrients"},{"key":"ref5","article-title":"Mental health and covid-19","author":"World Health Organization","journal-title":"World Health Organization"},{"key":"ref6","article-title":"Covid-19 and mental health","author":"U.S. Department of Health and Human Services","journal-title":"National Institute of Mental Health"},{"issue":"2","key":"ref7","first-page":"21","article-title":"Adolescent Brain Development and Drugs","volume":"18","author":"K. C. Winters","year":"2011","journal-title":"The prevention researcher"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"D. E. Nichols","year":"2004","journal-title":"Pharmacology & Therapeutics"},{"issue":"10","key":"ref9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1360-0443.1993.tb02018.x","article-title":"Adverse consequences of lysergic acid diethylamide","volume":"88","author":"H. D. Abraham","year":"1993","journal-title":"Addiction"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"D. E. Nichols","year":"2016","journal-title":"Pharmacological Reviews"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"M. W. Johnson","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"ref12","article-title":"Hallucinogen addiction: Types & effects of mind-altering drugs","author":"L. Miller","year":"2023","journal-title":"American Addiction Centers"},{"key":"ref13","article-title":"Hallucinogen abuse signs & symptoms","year":"2018","journal-title":"Longleaf Hospital"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.727117","article-title":"Psychedelics and Other Psychoplastogens for Treating Mental Illness","volume":"12","author":"M. V. Vargas","year":"2021","journal-title":"Frontiers in Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/rmhp.s300656","article-title":"The Use of Classic Hallucinogens\/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges","volume":"14","author":"R. G. Dos Santos","year":"2021","journal-title":"Risk Management and Healthcare Policy"},{"issue":"14","key":"ref16","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1503\/cmaj.141124","article-title":"Psychedelic medicine: a re-emerging therapeutic paradigm","volume":"187","author":"K. W. Tupper","year":"2015","journal-title":"Canadian Medical Association Journal"}],"container-title":["Health Psychology Research"],"original-title":[],"link":[{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/202503311536288b6c24533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/202503311536288b6c24533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:24:08Z","timestamp":1760343848000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthpr.org\/journal\/HPR\/13\/1\/10.52965\/001c.127794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.127794","relation":{},"ISSN":["2420-8124"],"issn-type":[{"value":"2420-8124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}